Clinical Study of Metoprolol Combined with Sacubitril Valsartan Sodium in the Treatment of Coronary Heart Disease Complicated with Chronic Heart Failure
Objective To investigate the clinical efficacy of metoprolol combined with sacubitril valsartan sodium in the treatment of coronary heart disease(CHD)complicated with chronic heart failure(CHF),and its effects on ventricular remodeling,inflammatory factors and miRNA.Methods A total of 160 patients with CHD compliccated with CHF in the hospital from January 2022 to June 2023 were selected and divided into the observation group and the control group by the random number table method,with 80 cases in each group.The patients in the two groups were treated with metoprolol,on this basis,the patients in the observation group were treated with sacubitril valsartan sodium.Both groups were continuously treated for three months.Results The total effective rate in the observation group was 90.00%,which was significantly higher than 77.50%in the control group(P<0.05).After treatment,the levels of serum N-terminal pro-B-type natriuretic peptide(NT-proBNP),matrix metalloproteinase-9(MMP-9),matrix metalloproteinase-2(MMP-2),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP),the left ventricular end-diastolic diameter(LVEDd),the left ventricular end-systolic diameter(LVESd),and the score of Minnesota Living with Heart Failure Questionnaire(MLHFQ)in the observation group were significantly lower than those in the control group(P<0.05),while the adiponectin(APN)level,left ventricular ejection fraction(LVEF),miR-26a-5p,and miR-451a in the observation group were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was comparable to that in the control group(6.25%vs.8.75%,P>0.05).Conclusion Metoprolol combined with sacubitril valsartan sodium has good clinical efficacy and safety in the treatment of CHD complicated with CHF,it can promote ventricular remodeling,reduce inflammatory factor levels,upregulate miRNA expression,and improve cardiac function.
metoprololsacubitril valsartan sodiumcoronary heart diseasecoronary heart failureinflammatory factorscardiac function
国家科技期刊平台
NSTL
万方数据
